Aytu BioPharma outlines EXXUA launch strategy and expects breakeven at $17.3M quarterly net revenue as ADHD portfolio remains resilient (NASDAQ:AYTU)
Aytu BioPharmaAytu BioPharma(US:AYTU) Seeking Alpha·2026-02-04 01:01

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]